Skip to main content
. 2020 May 12;20:408. doi: 10.1186/s12885-020-06920-3

Fig. 3.

Fig. 3

Frequency of p.T790M acquisition. Frequency of total p.T790M acquisition in patients under reversible (a) and irreversible (b) EGFR TKI therapy for > 6 months, respectively. Chi Square statistics identified a significant difference in the prevalence of p.T790M mutation in reversible vs irreversible EGF TKI treated patients (p = 0.019)